

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Organic Preparations and Procedures International

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t902189982>

A NOVEL SYNTHESIS OF 2,3-DIHYDRO[1,5]BENZOTHAZEPIN-4(5H)-ONES

Jean-Charles Lancelot^a; Bertrand Letois^a; Carmela Saturnono^a; Paolo De Caprariis^b; Max Robba^a

^a Laboratoire de Chimie Thérapeutique U. F. R. des Sciences Pharmaceutiques I rue Vaubénard, Caen Cedex, France ^b Dipartimento di Chimica Farmaceutica e Tossicologica Facoltà di Farmacia, Università di Napoli, Napoli, Italia

To cite this Article Lancelot, Jean-Charles , Letois, Bertrand , Saturnono, Carmela , De Caprariis, Paolo and Robba, Max(1992) 'A NOVEL SYNTHESIS OF 2,3-DIHYDRO[1,5]BENZOTHAZEPIN-4(5H)-ONES', *Organic Preparations and Procedures International*, 24: 2, 204 – 208

To link to this Article: DOI: 10.1080/00304949209355701

URL: <http://dx.doi.org/10.1080/00304949209355701>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

2327(1988); b) K. Harano, I. Shinohara, S. Sugimoto, T. Matsuoka and T. Hisano, *Chem. Pharm. Bull. Japan*, **37**, 576 (1989) and references cited therein.

- 4) The activation enthalpy and entropy for the reaction of *O*-ethyl *S*-methyl xanthate with PP in DMSO are 24.7 kcal/mol and -11 e.u. respectively. In the reaction, a coloration due to a charge transfer complex^{3b} was not observed in contrast to the case of pyridine *N*-oxides.
- 5) H. Yoshida, *Bull. Chem. Soc. Japan*, **42**, 1948(1969) and references cited therein.
- 6) Reaction of *O,S*-dimethyl xanthate with triethylenediamine gave the stable quaternary salt. The reaction with PP may proceed through the formation of a similar quaternary salt which may easily dissociate by heating.
- 7) T. Kawata, K. Harano and T. Taguchi, *Chem. Pharm. Bull. Japan*, **21**, 604 (1973).

A NOVEL SYNTHESIS OF 2,3-DIHYDRO[1,5]BENZOTHIAZEPIN-4(5H)-ONES

Submitted by Jean-Charles Lancelot[†], Bertrand Letois[†], Carmela Saturnino[†],
(12/26/91) Paolo De Caprariis^{††} and Max Robba^{*†}

[†] *Laboratoire de Chimie Thérapeutique U. F. R. des Sciences Pharmaceutiques 1 rue Vaubénard, 14032 Caen Cedex, FRANCE*

^{††} *Dipartimento di Chimica Farmaceutica e Tossicologica Facoltà di Farmacia Università di Napoli, via D. Montesano 49, 80138 Napoli, ITALIA*

Benzothiazepines such as *Diltiazem*¹ or *Thiazesim*² are currently used as antidepressant, coronary vasodilator and antiangina agents. The present paper describes the preparation of new 2,3-dihydro[1,5]benzothiazepines diversely substituted at the 2-position.




TABLE 1. 2,3-Dihydro[1,5]benzothiazepin-4(5H)-ones

Cmpd.	Yield (%)	mp. ^a (°C)	Time (hrs)	IR (cm ⁻¹)	¹ H NMR (δ) ppm
3a	66	164	6	3160, 1660	9.78 (NH), 8.56, 8.46, 7.63, 7.60 (Ar, pyridyl), 7.50, 7.25 (Ar, H), 5.06 (1H, CH), 2.70 (2H, CH ₂).
3b	76	192	6	3160, 1655	9.78 (NH), 7.90, 7.25, 6.87 (Ar, H), 4.90 (1H, CH), 2.43 (2H, CH ₂).
3c	71	179	6	3160, 1660	9.96 (NH), 7.43, 7.00 (Ar, H), 5.03 (1H, CH), 2.63 (2H, CH ₂).
3d	72	159 ^b	7	3180, 1670	9.96 (NH), 7.46, 7.06 (Ar, H), 7.00, 6.36, 6.26 (Ar, furyl), 4.96 (1H, CH), 2.63 (2H, CH ₂).
3e	70	171	7	3160, 1670	10.00 (NH), 7.46, 7.15, 7.03 (Ar, H), 7.03 (Ar, H), 5.30 (1H, CH), 2.73 (2H, CH ₂).
3f	75	169	8	3160, 1655	9.93 (NH), 7.46, 7.10 (Ar, H), 6.67, 6.53 (Ar, thienyl), 5.16 (1H, CH), 2.66 (2H, CH ₂), 2.33 (3H, CH ₃).
3g	78	178	8	3180, 1660	10.00 (NH), 7.33, 7.16 (Ar, H), 6.96, 6.80 (Ar, thienyl), 5.16 (1H, CH), 2.66 (2H, CH ₂).
3h	76	155 ^b	6	3150, 1670	10.00 (NH), 7.45, 7.10 (Ar, H), 5.06 (1H, CH), 2.70, (2H, CH ₂).
3i	69	117 ^b	4	3180, 1680	9.73 (NH), 7.36, 7.06 (Ar, H), 3.70 (1H, CH), 2.46 (2H, CH ₂), 1.46 (8H, CH ₂), 0.96 (3H, CH ₃).

a) Crystallized from acetonitrile unless otherwise noted. b) Ethanol

These compounds were obtained by heating an intimate mixture of *o*-aminothiophenol with cinnamic or acrylic acids **2**³ at 170°. The 2,3-dihydro[1,5]benzothiazepin-4(5H)-ones (**3a-3i**) were isolated in 66-78% yield. Acetylation of these compounds with acetic anhydride in acetic acid at 60° led to 5-acetyl-2,3-dihydro [1,5]benzothiazepin-4(5H)-ones (**4a-4i**). The structure of these benzothiazepines was confirmed by NMR spectra.

EXPERIMENTAL SECTION

Melting points were determined on a Kofler WME type apparatus and were uncorrected. IR spectra were recorded as KBr pellets on a Philips P. U. spectrometer. ¹H NMR spectra were obtained on a Varian EM 390 spectrometer at 90 MHz in DMSO-d₆ with TMS as an internal reference and chemical shifts are expressed as δ (ppm). The thienylacrylic and cinnamic acids were prepared according to the literature method.⁹

TABLE 2. 5-Acetyl-2,3-dihydro[1,5]benzothiazepin-4-ones

Cmpd.	Yield (%)	mp. ^a (°C)	Time (hrs)	IR (cm ⁻¹)	¹ H NMR (δ) ppm
4a	77	131	1	1710, 1700	8.40, 7.46, 7.30 (Ar, H), 4.96 (1H, CH), 2.76 (2H, CH ₂), 2.58 (3H, CH ₃).
4b	70	150	1	1710, 1700	7.95, 7.30, 6.90 (Ar, H), 4.92 (1H, CH), 2.41 (2H, CH ₂), 2.41 (3H, COCH ₃).
4c	69	141	1	1715, 1700	7.46, 7.03 (Ar, H), 4.86 (1H, CH), 2.73 (2H, CH ₂), 2.56 (3H, COCH ₃).
4d	78	120	1	1710, 1700	7.20, 6.06, 5.80 (Ar, H), 4.73 (1H, CH), 2.56 (2H, CH ₂), 2.38 (3H, COCH ₃).
4e	85	112	1	1715, 1710	7.40, 7.13 (Ar, H), 5.10 (1H, CH), 2.90 (2H, CH ₂), 2.60 (3H, COCH ₃).
4f	76	132	0.5	1710, 1700	7.43, 6.56 (Ar, H), 5.06 (1H, CH), 2.86 (2H, CH ₂), 2.36 (3H, CH ₃), 2.60 (3H, COCH ₃).
4g	80	149	1	1710, 1695	7.40, 6.93, 6.63 (Ar, H), 5.10 (1H, CH), 2.96 (2H, CH ₂), 2.53 (3H, COCH ₃).
4h	74	127	1.3	1710, 1700	7.40, 7.16, 6.70 (Ar, H), 4.90 (1H, CH), 2.80 (2H, CH ₂), 2.66 (3H, COCH ₃).
4i	69	130	1	1710, 1700	7.40, 7.10 (Ar, H), 3.76 (1H, CH), 2.50 (2H, CH ₂), 1.50 (8H, (CH ₂) ₄), 0.96 (3H, CH ₃), 2.68 (3H, COCH ₃).

a) Crystallized from diethyl ether .

2,3-Dihydro-2-(3-pyridyl)[1,5]benzothiazepin-4(5H)-one (3a). General Procedure.- A viscous mixture of equimolar amounts (0.1 mol) of **1** and of 3-(3-pyridyl)acrylic acid (**2**) was heated with stirring for 6 hrs at 170°. The residue was triturated at 5° with 100 mL ethanol. The resulting crystals were collected and recrystallized from acetonitrile to give 17 g (66%) of **3a**. The data for the products are summarized in the Table 1 .

5-Acetyl-2,3-dihydro-2-(3-pyridyl)[1,5]benzothiazepin-4-one (4a). General Procedure.- A solution of 5 g (0.0195 mol) of 2,3-dihydro-2-(3-pyridyl)[1,5]benzothiazepin-4-one (**3a**) in 10 mL of acetic anhydride and 15 mL of acetic acid was heated for 1 hr at 60°. After dilution with water and cooling at 5°, white crystals deposited. The solid was collected and crystallized from diethyl ether to give 4.50 g (77%) of **4a**. The data for products **4b-4i** are summarized in the Table 2.

TABLE 3. Elemental Analysis Data of Compounds 3 and 4.

Cmpd.	Elemental Analysis Data					
	C		H		N	
	Calcd.	Found	Calcd.	Found	Calcd.	Found
3a	65.62	65.60	4.72	4.70	10.93	10.97
3b	60.00	60.00	4.03	4.06	9.33	9.35
3c	65.91	65.96	4.42	4.50	5.12	5.20
3d	63.67	63.70	4.52	4.55	5.71	5.80
3e	59.77	59.81	4.24	4.31	5.36	5.42
3f	61.09	61.12	4.76	4.80	5.09	5.10
3g	48.15	48.22	3.10	3.15	4.31	4.45
3h	59.77	59.82	4.24	4.30	5.36	5.38
3i	67.44	67.52	7.68	7.71	5.62	5.58
4a	64.42	64.50	4.73	4.80	9.39	9.45
4b	59.65	59.75	4.12	4.20	8.18	8.22
4c	64.74	64.82	4.47	4.48	4.44	4.50
4d	62.71	62.76	4.56	4.60	4.88	4.92
4e	59.40	59.47	4.32	4.40	4.62	4.72
4f	60.56	60.70	4.77	4.80	4.41	4.52
4g	47.12	47.22	3.16	3.20	3.66	3.76
4h	59.40	59.62	4.32	4.34	4.62	4.80
4i	65.95	66.10	7.27	7.32	4.81	4.94

REFERENCES

1. H. Kugita, H. Inoue, M. Ikezaki and S. Takeo, *Chem. Pharm. Bull. Jpn.*, **18**, 2028 (1970); *ibid.*, **19**, 595 (1971).
2. J. Krapcho, E. R. Spitzmiller and C. F. Turk, *J. Med. Chem.*, **6**, 544 (1963)
3. M. Sakuma, M. Yoshikawa and Y. Sato, *Chem. Pharm. Bull. Jpn.*, **19**, 995 (1971).
4. T. Nagao, M. Sato, H. Nakajima and A. Kiyomoto, *ibid.*, **21**, 92 (1973).
5. M. A. Matlib, A. Depover and A. Schwartz, *Eur. J. Pharm.*, **89**, 327 (1983).
6. T. Hashijama, A. Watanabe, H. Inoue, M. Konda, M. Takeda, S. Murata and T. Nagao, *Chem. Pharm. Bull. Jpn.*, **33**, 634 (1985).
7. S. Ohno, K. Izumi, K. Mizukoshi, K. Kato and M. Hori, *ibid.*, **31**, 1780 (1983).

8. M. Miyazaki, T. Iwakuma and T. Tanaka, *ibid.*, **26**, 2889 (1978).
9. W. Raich and C. Hamilton, *J. Am. Chem. Soc.*, **79**, 3800 (1957).